Results of a phase II trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603).

Yasuyuki Kawamoto,Satoshi Yuki,Kentaro Sawada,Michio Nakamura,Osamu Muto,Susumu Sogabe,Y. Shindo,Atsushi Ishiguro,Atsushi Sato,Yasushi Tsuji,Masayoshi Dazai,Hiroyuki Okuda,Takahide Sasaki,Kazuaki Harada,Shintaro Nakano,Hiroshi Nakatsumi,Mari Sekiguchi,Yuh Sakata,Naoya Sakamoto,Yoshito Komatsu

Results of a phase II trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603).

2021

217Background: Ramucirumab (RAM) is a fully human IgG1 monoclonal vascular endothelial growth factor receptor-2 (VEGFR-2) antibody. The RAINBOW trial showed RAM plus paclitaxel (PTX) increased over...

Keywords:

Paclitaxel
Medicine
Cancer research
Irinotecan
Vascular endothelial growth factor
Monoclonal
Ramucirumab
Antibody
second line treatment
advanced gastric cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations